Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

Revolution Medicines maintains a strong buy rating following FDA approval of RASONQUE for 2nd-line m

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) i

Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonras

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the pr

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra

It's a cancer medication with immense potential. In clinical testing, the pill was shown to double t

Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cance

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed pro

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 pre

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms is

Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90%

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials sho

This release contains multimedia assets available for download here

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,'

The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patie

The U.S. Food and Drug ​Administration on Wednesday approved ‌Revolution Medicines' targeted drug fo

Druckenmiller added roughly 26.5% to his position in Revolution Medicines in Q2. Analysts like the b

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perfor

Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giv

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) hit a new 52-week high during mid-day tr

Companies also enter a separate regional rights agreement granting BeOne exclusive development and c

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Na

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an

Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology pl

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook agai

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investmen

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the a

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targete

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the